RNASEH2A

Across TCGA pan-cancer cohorts, RNASEH2A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RNASEH2A data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RNASEH2A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNASEH2A expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where RNASEH2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.637	0.892	<.001	116	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.698	.004	28	view →
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	20	view →
COAD	DFS	Median	IV	0.493	0.944	.031	12	view →
UCEC	DFS	Quartile	All	0.737	0.936	.026	12	view →
PDAC	DFS	Quartile	All	0.401	0.212	.032	7	view →
GBM	DFS	Tertile	All	0.472	0.209	.007	5	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RNASEH2A–HNSC (DFS)

Open the HNSC breakdown →